Work here is focused on developing innovative therapies for cancer and infection using powerful new technologies such as rapid sequencing of microbial genomes and gene identification in pathogenic microbes.
Since opening, our scientists in Boston have discovered three potential drugs that are under development to treat different cancers including breast, ovarian, thyroid and prostate cancer, and two novel-class candidate drugs to potentially treat serious skin infections, serious cases of chronic bronchitis and serious pneumonias.
In January 2007, we announced a $100m research investment in a new facility at Boston to strategically boost our research effort in cancer and infection which continue to be critical areas of unmet need. Construction of the new facility will begin during the first quarter of 2007 with scheduled completion by mid 2009. It will accommodate up to 100 additional researchers who will join the more than 400 employees currently working at this site.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At 21-Nov-2009 02:22 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
